Financial Performance - The company's operating revenue for the first half of 2024 was ¥908,526,752.98, a decrease of 34.94% compared to ¥1,396,475,774.51 in the same period last year[11]. - The net profit attributable to shareholders was a loss of ¥52,464,103.69, representing a decline of 348.31% from a profit of ¥21,128,073.92 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥74,540,507.67, a decrease of 1,182.63% compared to a profit of ¥6,885,105.47 last year[12]. - The basic earnings per share were -¥0.1035, a decline of 351.82% from ¥0.0411 in the same period last year[12]. - The diluted earnings per share were also -¥0.1035, reflecting the same percentage decline as the basic earnings per share[12]. - The company reported a total non-recurring gains and losses of ¥22,076,403.98, with significant contributions from government subsidies and financial asset disposals[15]. - The company reported a significant decrease in investment amounting to ¥3.01 million, down 97.57% from ¥124 million in the same period last year[52]. - The company reported a loss of 1.173 million CNY from foreign exchange forward contracts during the reporting period, with a total initial investment of 0 CNY and an ending amount of 0 CNY[55]. - The company reported a total cash outflow of -203,677,623.91 CNY for the first half of 2024, compared to -561,779,546.60 CNY in the same period of 2023, showing a significant improvement[124]. Cash Flow and Assets - The net cash flow from operating activities improved to -¥121,178,619.00, a 79.53% increase from -¥592,060,407.58 in the previous year[12]. - Cash and cash equivalents at the end of the reporting period were ¥1.47 billion, representing 22.36% of total assets, down 1.60% from the previous year[47]. - Accounts receivable increased to ¥1.12 billion, accounting for 17.01% of total assets, up 0.82% year-on-year[47]. - Inventory reached ¥1.02 billion, which is 15.48% of total assets, an increase of 1.15% compared to the previous year[47]. - The company's total assets at the end of the reporting period amount to CNY 2,958,266,404.89, reflecting a significant change in the asset structure[128]. - The company's total equity decreased to CNY 2.96 billion in the first half of 2024 from CNY 3.08 billion in the same period of 2023, a decline of 4.2%[118]. Market Position and Growth - The company is positioned within the rapidly growing medical device sector, specifically in the in vitro diagnostics field, which is crucial for clinical decision-making[16]. - The global in vitro diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 4.8% from 2020 to 2027, with North America holding over 40% of the market share[17]. - The Chinese in vitro diagnostics market is expected to maintain a CAGR of approximately 10% over the next five years, reaching a market size of ¥190 billion by 2028[18]. - The immunodiagnostics segment holds the largest market share in China, accounting for 37%, followed by molecular diagnostics at 22% and biochemical diagnostics at 15%[18]. - The company is expected to benefit from the increasing healthcare expenditure and the rising demand for diagnostic services in emerging markets[17]. - The company is actively involved in the development of new diagnostic technologies and expanding its market presence in both domestic and international markets[20]. Research and Development - Research and development expenses amounted to ¥134,786,752.14, a decrease of 13.00% from ¥154,933,153.74[43]. - The company continues to invest in R&D to enhance its product offerings and service systems[26]. - The company has made significant investments in research and development for new products and technologies, aiming to enhance its market position[131]. - The company emphasizes continuous investment in R&D to keep pace with industry trends and avoid being replaced by competitors[70]. Regulatory and Compliance - The company has established a regulatory affairs department to ensure timely product registration in domestic and international markets, reducing registration risks[69]. - The company has revised its governance structure and internal regulations to enhance shareholder rights and ensure compliance with legal standards[77]. - There were no significant environmental violations or penalties reported during the reporting period, indicating compliance with environmental regulations[76]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[2]. - The company has established a performance-oriented compensation management system to ensure fair growth opportunities for employees[79]. - The company actively engages in investor relations through multiple channels to ensure transparency and protect shareholder interests[78]. - The company has undergone a change in control, with Xi'an Zhitong becoming the controlling shareholder[85]. Financial Management and Risk - The company aims to mitigate foreign exchange risks through hedging strategies, which are based on actual operational needs[55]. - The company has established a management system for hedging operations to ensure compliance and risk control in foreign exchange hedging activities[56]. - The company has not engaged in speculative derivative investments during the reporting period[57]. - The company has not undertaken any external guarantees during the reporting period, maintaining a conservative financial approach[88]. Product Development and Innovation - The company launched new products in the biochemical immunoassay field, including the mini LAS automated line, targeting the grassroots hospital market to meet automation needs[24]. - The company is focusing on expanding its product line in the field of molecular diagnostics, accelerating the integration of this business line[25]. - The company continues to innovate in the field of diagnostic reagents, covering a wide range of diseases including infectious diseases, cardiovascular health, and genetic testing[30]. - The company has launched a range of new products, including high-sensitivity hepatitis B and C nucleic acid detection reagents, enhancing its product portfolio in the molecular diagnostics field[29]. Strategic Partnerships and Collaborations - The company is expanding its market presence through strategic partnerships and collaborations with domestic and international brands to enhance its product offerings[29]. - The company exports products to over 100 countries and regions, establishing long-term partnerships with thousands of domestic and international distributors[22]. Financial Ratios and Performance Metrics - The company's interest coverage ratio is -0.82, down 113.83% from 5.93 in the previous year, indicating a significant decline in profitability[111]. - The cash interest coverage ratio is -18.86, showing an improvement of 17.14% compared to -22.76 in the previous year[111]. - The company's current liquidity ratio is 4.95, an increase of 3.56% compared to the previous year, while the debt-to-asset ratio is 26.40%, a decrease of 0.39%[111].

近日，上海科华生物工程股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的医疗器械注册证（体外诊断试剂）。具体情况如下： | 证券代码：002022 | 证券简称：科华生物 | 公告编号：2024-070 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 上海科华生物工程股份有限公司 关于产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 上海科华生物工程股份有限公司董事会 2024 年 8 月 27 日 | 1 | 试剂盒（化学发光 | 国械注准 | | | | | | | 本产品用于体外定量测定 人血清中异常凝血酶原的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 法） | 20243401590 | 2029 | 年 | 至 08 | 月 | 22 | 日 | | | 序号 | 产品名称 异常凝血酶原测定 | 注册证编号 | 2024 | 年 | 注册证有效期 08 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | | | 公告编号：2024-069 | | 债券代码：128124 | 债券简称：科华转债 | | 上海科华生物工程股份有限公司 关于产品获得医疗器械注册证的公告 以上新产品医疗器械注册证的取得，丰富了公司产品线，将对公司业务发展 具有正面影响。公司目前尚无法预测上述产品对公司未来营业收入的影响，敬请 投资者给予关注并注意投资风险。 特此公告。 上海科华生物工程股份有限公司董事会 2024 年 8 月 13 日 近日，上海科华生物工程股份有限公司（以下简称"公司"）控股子公司西 安天隆科技有限公司收到国家药品监督管理局颁发的医疗器械注册证。具体情况 如下： | 1 | 全自动核 | | | 基于磁珠法核酸提取和实时荧光 PCR 检测原理，与配套的检测试剂 | | --- | --- | --- | --- | --- | | | 酸提取及 | 国械注准 | 2024 年 08 月 09 日 | 共同使用，在临床 ...

| 证券代码：002022 | 证券简称：科华生物 | 公告编号：2024-068 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 上海科华生物工程股份有限公司 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引第 9 号 ——回购股份》（以下简称"《回购指引》"）等相关规定，公司在回购期间，应在每个 月的前三个交易日内披露截至上月末的回购进展情况。现将公司截至 2024 年 7 月 31 日的回购进展情况公告如下： 一、公司回购股份的进展情况 截至 2024 年 7 月 31 日，公司累计通过股份回购专用证券账户以集中竞价交易方 式回购公司股份数量为 11,775,300 股，占公司目前总股本的比例 2.29%，最高成交 价格 10.68 元/股，最低成交价格为 5.10 元/股，成交金额为 89,212,672.71 元（不 含交易费用）。本次回购符合相关法律法规的规定及公司回购股份方案的要求。 二、其他说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托时段 符合《回购指引》第十七条、十八条的相关规定。 1、公司 ...

| 证券代码：002022 证券简称：科华生物 债券简称：科华转债 | 公告编号：2024-067 | | --- | --- | | 债券代码：128124 | | 上海科华生物工程股份有限公司 关于可转换公司债券 2024 年付息公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"科华转债"将于 2024 年 7 月 29 日按面值支付第四年利息，每 10 张"科 华转债"（面值 1,000 元）利息为 12.00 元（含税）； 2、债权登记日：2024 年 7 月 26 日； 3、除息日：2024 年 7 月 29 日； 4、付息日：2024 年 7 月 29 日； 5、"科华转债"票面利率：第一年 0.30%、第二年 0.50%、第三年 0.80%、 第四年 1.20%、第五年 1.50%、第六年 2.00%。 6、"科华转债"本次付息的债权登记日为 2024 年 7 月 26 日，凡在 2024 年 7 月 26 日（含）前买入并持有本期债券的投资者享有本次派发的利息；2024 年 7 月 26 日卖出本期债券的投资者不享有本次派 ...

证券代码：002022 证券简称：科华生物 公告编号：2024-065 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 第十届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （一）审议通过《关于不向下修正"科华转债"转股价格的议案》 经审议，公司董事会决定本次不向下修正"科华转债"转股价格，且自本次 董事会审议通过之日起未来六个月（即 2024 年 7 月 20 日至 2025 年 1 月 19 日） 内，如再次触发"科华转债"转股价格向下修正条款，亦不提出向下修正方案。 具体详见公司于同日在《证券时报》、《中国证券报》、《上海证券报》及巨潮 资讯网（http://www.cninfo.com.cn）披露的《关于不向下修正"科华转债"转 股价格的公告》（公告编号：2024-066）。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 三、备查文件 1、第十届董事会第五次会议决议。 特此公告。 上海科华生物工程股份有限公司董事会 一、董事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届 ...

一、可转换公司债券基本情况 证券代码：002022 证券简称：科华生物 公告编号：2024-066 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 关于不向下修正"科华转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、截至 2024 年 7 月 19 日，上海科华生物工程股份有限公司（以下简称"公 司"）股票已出现在任意连续 20 个交易日中至少有 10 个交易日的收盘价低于当期 转股价格的 90%的情形，已触发"科华转债"转股价格的向下修正条款。 2、公司于 2024 年 7 月 19 日召开第十届董事会第五次会议，审议通过了《关 于不向下修正"科华转债"转股价格的议案》，公司董事会决定本次不向下修正"科 华转债"转股价格，且自本次董事会审议通过之日起未来六个月（即 2024 年 7 月 20 日至 2025 年 1 月 19 日）内，如再次触发"科华转债"转股价格向下修正条款， 亦不提出向下修正方案。自本次董事会审议通过之日起满六个月之后，从 2025 年 1 月 20 日开始重新起算，若再次触 ...

| 证券代码：002022 | 证券简称：科华生物 公告编号：2024-064 | | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 以上新产品医疗器械注册证的取得，丰富了公司产品线，将对公司业务发展 具有正面影响。公司目前尚无法预测上述产品对公司未来营业收入的影响，敬请 投资者给予关注并注意投资风险。 特此公告。 上海科华生物工程股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，上海科华生物工程股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的医疗器械注册证（体外诊断试剂）。具体情况如下： | 序号 | 产品名称 | 注册证编号 | | | 注册证有效期 | | | 适用范围/预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 人类免疫缺陷病毒 1 型（HIV-1）核酸 | 国械注准 | 2024 | 年 | 07 至 | 月 | 17 日 | 该产品用于定量检测人血 清或血浆样本中的人类免 | | | ...

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2024-063 | 上海科华生物工程股份有限公司 关于"科华转债"预计触发 转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 4、转股时间：2021 年 2 月 3 日至 2026 年 7 月 27 日 5、根据《上海科华生物工程股份有限公司公开发行可转换公司债券募集说 明书》（以下简称"《募集说明书》"）的规定，在上海科华生物工程股份有限公司 （以下简称"公司"）本次发行的可转债存续期间，当公司股票在任意连续 20 个 交易日中至少有 10 个交易日的收盘价低于当期转股价格的 90%时，公司董事会 有权提出转股价格向下修正方案并提交公司股东大会表决。本次触发转股价格 修正条件的期间从 2024 年 7 月 6 日起算，自 2024 年 7 月 8 日至 2024 年 7 月 12 日，公司股票已有 5 个交易日的收盘价低于当期转股价格的 90%，预计 ...

Financial Performance Expectations - The company expects a net profit loss between 40 million to 57 million CNY for the first half of 2024, compared to a profit of 21.1281 million CNY in the same period last year[7]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 62 million to 79 million CNY, compared to a profit of 6.8851 million CNY last year[7]. - Basic earnings per share are expected to be a loss between 0.0778 CNY to 0.1108 CNY, compared to a profit of 0.0411 CNY per share in the previous year[7]. - The financial data in the performance forecast has not been audited by registered accountants[8]. Performance Decline Factors - The decline in performance is attributed to market environment changes, intensified industry competition, and the implementation of centralized procurement policies[9]. Strategic Initiatives - The company maintains a high proportion of R&D investment to drive product upgrades and explore new product lines, aiming for comprehensive coverage in the testing field[9]. - The company is focused on a strategy of "comprehensive and precise" and "integrated innovation," aiming to meet national health needs[9]. - Efforts are being made to improve domestic and international sales channels while accelerating overseas market expansion[9]. - The company is implementing lean management to enhance operational efficiency and quality[9]. International Competitiveness - The Italian subsidiary has obtained 57 IVDR certificates in the first half of the year, enhancing international competitiveness[9].